A PSMA-targeted theranostic agent for photodynamic therapy

Ying Chen, Samit Chatterjee, Ala Lisok, Il Minn, Mrudula Pullambhatla, Bryan Wharram, Yuchuan Wang, Jiefu Jin, Zaver M. Bhujwalla, Sridhar Nimmagadda, Ronnie C. Mease, Martin G. Pomper

Research output: Research - peer-reviewArticle

Abstract

Prostate-specific membrane antigen (PSMA) is over-expressed in the epithelium of prostate cancer and in the neovasculature of many non-prostate solid tumors. PSMA has been increasingly used as a target for cancer imaging and therapy. Here we describe a low-molecular-weight theranostic photosensitizer, YC-9, for PSMA-targeted optical imaging and photodynamic therapy (PDT). YC-9 was synthesized by conjugating IRDye700DX N-hydroxysuccinimide (NHS) ester with a PSMA targeting Lys-Glu urea through a lysine-suberate linker in suitable yield. Optical imaging in vivo demonstrated PSMA-specific tumor uptake of YC-9 with rapid clearance from non-target tissues. PSMA-specific cell kill was demonstrated with YC-9 in vitro through PDT in PSMA+ PC3-PIP and PSMA PC3-flu cells. In vivo PDT in mice bearing PSMA+ PC3-PIP tumors at 4 h post-injection of YC-9 (A total of four PDT sessions were performed, 48 h apart) resulted in significant tumor growth delay, while tumors in control groups continued to grow. PDT with YC-9 significantly increased the median survival of the PSMA+ PC3-PIP tumor mice (56.5 days) compared to control groups [23.5–30.0 days, including untreated, light alone, YC-9 alone (without light) and non-targeted IRDye700DX PDT treatment groups], without noticeable toxicity at the doses used. This study proves in principle that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as prostate tumors, and may also be useful against non-prostate tumors by virtue of neovascular PSMA expression.

LanguageEnglish (US)
Pages111-116
Number of pages6
JournalJournal of Photochemistry and Photobiology B: Biology
Volume167
DOIs
StatePublished - Feb 1 2017

Fingerprint

Photochemotherapy
human glutamate carboxypeptidase II
Theranostic Nanomedicine
antigens
therapy
membranes
Neoplasms
tumors
Therapeutics
Optical Imaging
Light
Control Groups
mice
cancer
cells
lysylglutamic acid
Photosensitizing Agents
Lysine
Urea
Prostate

Keywords

  • Molecular imaging
  • Optical imaging
  • PDT
  • Prostate cancer
  • Prostate-specific membrane antigen

ASJC Scopus subject areas

  • Radiation
  • Radiological and Ultrasound Technology
  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

A PSMA-targeted theranostic agent for photodynamic therapy. / Chen, Ying; Chatterjee, Samit; Lisok, Ala; Minn, Il; Pullambhatla, Mrudula; Wharram, Bryan; Wang, Yuchuan; Jin, Jiefu; Bhujwalla, Zaver M.; Nimmagadda, Sridhar; Mease, Ronnie C.; Pomper, Martin G.

In: Journal of Photochemistry and Photobiology B: Biology, Vol. 167, 01.02.2017, p. 111-116.

Research output: Research - peer-reviewArticle

Chen Y, Chatterjee S, Lisok A, Minn I, Pullambhatla M, Wharram B et al. A PSMA-targeted theranostic agent for photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology. 2017 Feb 1;167:111-116. Available from, DOI: 10.1016/j.jphotobiol.2016.12.018
@article{0334ffbc243a4fc5ad824930e6117e5a,
title = "A PSMA-targeted theranostic agent for photodynamic therapy",
abstract = "Prostate-specific membrane antigen (PSMA) is over-expressed in the epithelium of prostate cancer and in the neovasculature of many non-prostate solid tumors. PSMA has been increasingly used as a target for cancer imaging and therapy. Here we describe a low-molecular-weight theranostic photosensitizer, YC-9, for PSMA-targeted optical imaging and photodynamic therapy (PDT). YC-9 was synthesized by conjugating IRDye700DX N-hydroxysuccinimide (NHS) ester with a PSMA targeting Lys-Glu urea through a lysine-suberate linker in suitable yield. Optical imaging in vivo demonstrated PSMA-specific tumor uptake of YC-9 with rapid clearance from non-target tissues. PSMA-specific cell kill was demonstrated with YC-9 in vitro through PDT in PSMA+ PC3-PIP and PSMA− PC3-flu cells. In vivo PDT in mice bearing PSMA+ PC3-PIP tumors at 4 h post-injection of YC-9 (A total of four PDT sessions were performed, 48 h apart) resulted in significant tumor growth delay, while tumors in control groups continued to grow. PDT with YC-9 significantly increased the median survival of the PSMA+ PC3-PIP tumor mice (56.5 days) compared to control groups [23.5–30.0 days, including untreated, light alone, YC-9 alone (without light) and non-targeted IRDye700DX PDT treatment groups], without noticeable toxicity at the doses used. This study proves in principle that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as prostate tumors, and may also be useful against non-prostate tumors by virtue of neovascular PSMA expression.",
keywords = "Molecular imaging, Optical imaging, PDT, Prostate cancer, Prostate-specific membrane antigen",
author = "Ying Chen and Samit Chatterjee and Ala Lisok and Il Minn and Mrudula Pullambhatla and Bryan Wharram and Yuchuan Wang and Jiefu Jin and Bhujwalla, {Zaver M.} and Sridhar Nimmagadda and Mease, {Ronnie C.} and Pomper, {Martin G.}",
year = "2017",
month = "2",
doi = "10.1016/j.jphotobiol.2016.12.018",
volume = "167",
pages = "111--116",
journal = "Journal of Photochemistry and Photobiology B: Biology",
issn = "1011-1344",
publisher = "Elsevier",

}

TY - JOUR

T1 - A PSMA-targeted theranostic agent for photodynamic therapy

AU - Chen,Ying

AU - Chatterjee,Samit

AU - Lisok,Ala

AU - Minn,Il

AU - Pullambhatla,Mrudula

AU - Wharram,Bryan

AU - Wang,Yuchuan

AU - Jin,Jiefu

AU - Bhujwalla,Zaver M.

AU - Nimmagadda,Sridhar

AU - Mease,Ronnie C.

AU - Pomper,Martin G.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Prostate-specific membrane antigen (PSMA) is over-expressed in the epithelium of prostate cancer and in the neovasculature of many non-prostate solid tumors. PSMA has been increasingly used as a target for cancer imaging and therapy. Here we describe a low-molecular-weight theranostic photosensitizer, YC-9, for PSMA-targeted optical imaging and photodynamic therapy (PDT). YC-9 was synthesized by conjugating IRDye700DX N-hydroxysuccinimide (NHS) ester with a PSMA targeting Lys-Glu urea through a lysine-suberate linker in suitable yield. Optical imaging in vivo demonstrated PSMA-specific tumor uptake of YC-9 with rapid clearance from non-target tissues. PSMA-specific cell kill was demonstrated with YC-9 in vitro through PDT in PSMA+ PC3-PIP and PSMA− PC3-flu cells. In vivo PDT in mice bearing PSMA+ PC3-PIP tumors at 4 h post-injection of YC-9 (A total of four PDT sessions were performed, 48 h apart) resulted in significant tumor growth delay, while tumors in control groups continued to grow. PDT with YC-9 significantly increased the median survival of the PSMA+ PC3-PIP tumor mice (56.5 days) compared to control groups [23.5–30.0 days, including untreated, light alone, YC-9 alone (without light) and non-targeted IRDye700DX PDT treatment groups], without noticeable toxicity at the doses used. This study proves in principle that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as prostate tumors, and may also be useful against non-prostate tumors by virtue of neovascular PSMA expression.

AB - Prostate-specific membrane antigen (PSMA) is over-expressed in the epithelium of prostate cancer and in the neovasculature of many non-prostate solid tumors. PSMA has been increasingly used as a target for cancer imaging and therapy. Here we describe a low-molecular-weight theranostic photosensitizer, YC-9, for PSMA-targeted optical imaging and photodynamic therapy (PDT). YC-9 was synthesized by conjugating IRDye700DX N-hydroxysuccinimide (NHS) ester with a PSMA targeting Lys-Glu urea through a lysine-suberate linker in suitable yield. Optical imaging in vivo demonstrated PSMA-specific tumor uptake of YC-9 with rapid clearance from non-target tissues. PSMA-specific cell kill was demonstrated with YC-9 in vitro through PDT in PSMA+ PC3-PIP and PSMA− PC3-flu cells. In vivo PDT in mice bearing PSMA+ PC3-PIP tumors at 4 h post-injection of YC-9 (A total of four PDT sessions were performed, 48 h apart) resulted in significant tumor growth delay, while tumors in control groups continued to grow. PDT with YC-9 significantly increased the median survival of the PSMA+ PC3-PIP tumor mice (56.5 days) compared to control groups [23.5–30.0 days, including untreated, light alone, YC-9 alone (without light) and non-targeted IRDye700DX PDT treatment groups], without noticeable toxicity at the doses used. This study proves in principle that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as prostate tumors, and may also be useful against non-prostate tumors by virtue of neovascular PSMA expression.

KW - Molecular imaging

KW - Optical imaging

KW - PDT

KW - Prostate cancer

KW - Prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=85007586466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007586466&partnerID=8YFLogxK

U2 - 10.1016/j.jphotobiol.2016.12.018

DO - 10.1016/j.jphotobiol.2016.12.018

M3 - Article

VL - 167

SP - 111

EP - 116

JO - Journal of Photochemistry and Photobiology B: Biology

T2 - Journal of Photochemistry and Photobiology B: Biology

JF - Journal of Photochemistry and Photobiology B: Biology

SN - 1011-1344

ER -